Table 1. Virucidal efficacies of Rox500-20, Pax500-20 and AFA-PBS-20 at −20°C.
| Solution type | Virus | Control | Viral titer (log10TCID50/ml) at different contact times | ||||
|---|---|---|---|---|---|---|---|
| 0 sec | 5 sec | 1 min | 10 min | 30 min | |||
| Rox500-20a | AIV | NT | 8.66 ± 0.07 | 7.50 ± 0.00 | 7.33 ± 0.35 | 7.00 ± 0.00 | 3.50 ± 0.00d |
| Pax500-20b | NT | 8.25 ± 0.11 | 7.00 ± 0.20 | 6.91 ± 0.07 | 5.50 ± 0.18 | 4.50 ± 0.00d | |
| Rox500-20 | NDV | NT | 9.33 ± 0.07 | 8.50 ± 0.00 | 8.00 ± 0.17 | 6.67 ± 0.47 | 6.16 ± 0.59d |
| Pax500-20 | NT | 9.08 ± 0.18 | 7.41 ± 0.20 | 7.58 ± 0.24 | 6.67 ± 0.18 | 5.50 ± 0.12d | |
| Rox500-20 | FAdV | NT | 8.50 ± 0.28 | 4.25 ± 0.38d | 3.50 ± 0.00d | NT | NT |
| Pax500-20 | NT | 8.58 ± 0.30 | 3.50 ± 0.17d | 3.17 ± 0.33d | NT | NT | |
| Rox500-20 | ARV | NT | 8.91 ± 0.08 | 3.58 ± 0.65d | 3.75 ± 0.25d | NT | NT |
| Pax500-20 | NT | 8.91 ± 0.08 | 4.58 ± 0.50d | 3.42 ± 0.30d | NT | NT | |
| AFA-PBS-20c | AIV | 8.50 ± 0.28 | NT | NT | NT | NT | 7.58 ± 0.13 |
| NDV | 9.25 ± 0.32 | NT | NT | NT | NT | 8.50 ± 0.20 | |
| FAdV | 8.25 ± 0.00 | NT | NT | NT | NT | 8.00 ± 0.00 | |
| ARV | 8.67 ± 0.07 | NT | NT | NT | NT | 8.25 ± 0.11 | |
a Quaternary ammonium compounds (QAC) -Rontect® from Scientific Feed Laboratory Co., Ltd. (Tokyo, Japan) was diluted 1:250 with 0.34% FdCa(OH)2 and mixed equally with the anti-freeze agent (AFA). b QAC-Pacoma®, Meiji Seika Pharma Co. (Tokyo, Japan) was diluted 1:250 with 0.34% FdCa(OH)2 and mixed equally with the AFA. c The anti-freeze agent (AFA) mixed with phosphate buffered saline (PBS) in equal amount as AFA-PBS-20. d Effective viral inactivation if ≥3 log10 tissue culture infective dose 50/ml (TCID50/ml). Data represent means ± standard error of 3 different experiments. ‘NT’ denoted as not tested.